Lonza nominates Pearl Huang. Lonza Group stock falls 1.54 percent
Published on 10/01/2026 at 12:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Lonza Group stock was trading at EUR 599.10 at Lang & Schwarz on October 1, 2026 at 12:06 p.m. CEST, down 1.54 percent from the prior close of EUR 608.50. On September 30, 2026, Lonza nominated Pearl Huang as an independent board member, subject to election at the May 2027 annual general meeting.
Board renewal adds a science profile
Huang is set to join Lonza's Strategy and Innovation Committee and Remuneration Committee if shareholders approve her appointment in May 2027. Angelica Kohlmann and Christoph Mäder will not stand for re-election at that meeting, making the nomination part of a broader board renewal.
The governance change gives Lonza additional biotechnology experience at board level. Huang previously held senior roles at Roche, GSK and Merck and currently serves on the boards of Waters Corporation and BB Biotech, according to the company release dated September 30, 2026.
Revenue rises 11.22 percent
Operating figures provide a stronger numerical anchor than the board reshuffle. According to Markets Insider on September 28, 2026, Lonza reported quarterly revenue of CHF 3.37 billion for the quarter ending June 30, 2026, versus CHF 3.03 billion a year earlier, an increase of 11.22 percent.
Net profit for the same quarter reached CHF 591 million, compared with CHF 426 million a year earlier, a 38.73 percent increase. Separately, Lonza's September 10, 2026 release said Half-Year 2026 sales were CHF 3.4 billion and CORE EBITDA was CHF 1.2 billion, linking the financial progress to continued investment in contract development and manufacturing capacity.
Barclays keeps a CHF 730 target
Analyst support remains part of the valuation backdrop. Markets Insider reported on September 28, 2026 that Barclays maintained a Buy rating and a CHF 730.00 price target; the target is 29.16 percent above the CHF 565.20 SIX quote from October 1, 2026. The same report cited a consensus target of CHF 705.43, while recent insider activity was described as negative.
The board reset meets a 1.54 percent drop
At Lang & Schwarz, Lonza stood at EUR 599.10 on October 1, 2026 at 12:06 p.m. CEST, versus the prior close of EUR 608.50, a minus 1.54 percent move. On the SIX Swiss Exchange, the finance quote showed CHF 565.20 at 11:55 a.m. CEST, with a market capitalization of CHF 39.5 billion and a 52-week range of CHF 454.60 to CHF 597.80.
The further course of trading is shown by the continuously updated real-time quote of Lonza Group stock.
Lonza Group stock facts
- Company: Lonza Group AG
- ISIN: CH0013841017
- Ticker: LONN
- Primary exchange: SIX Swiss Exchange
- Price Lang & Schwarz (as of October 1, 2026, 12:06 p.m. CEST): EUR 599.10
- Change versus prior close: minus 1.54 percent
- Prior close Lang & Schwarz (September 30, 2026): EUR 608.50
- Market capitalization: CHF 39.5 billion (as of October 1, 2026)
- 52-week range: CHF 454.60-597.80 (as of October 1, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: SMI
